Andrew Gaulden, PhD, is a 2026 NFXF Jr. Investigator. He is a translational neuroscientist who helps move CNS therapeutics from preclinical science toward the clinic. He develops EEG-based biomarkers for neurodevelopmental and psychiatric disorders and leads the analysis, partnering directly with industry sponsors and academic teams to turn preclinical programs into clear go/no-go decisions.